101 related articles for article (PubMed ID: 6396561)
61. [Successful vindesine treatment in the patient with blastic crisis of CML complicated with syndrome of inappropriate secretion of ADH secondary to vincristine].
Nishinarita S; Sasaki I; Hiranuma M; Sugai Y; Yoshizawa T; Sawada S; Amaki I
Rinsho Ketsueki; 1986 Oct; 27(10):1916-21. PubMed ID: 3469429
[No Abstract] [Full Text] [Related]
62. [Vindesine, a new cytostatic agent from the vinca alkaloids].
Goldhirsch A; Joss R; Sonntag RW; Brunner KW
Dtsch Med Wochenschr; 1980 Jun; 105(26):931-5. PubMed ID: 6931709
[No Abstract] [Full Text] [Related]
63. Phase II study of vindesine in patients with advanced breast cancer.
Walker BK; Raich PC; Fontana J; Subramanian VP; Rogers JS; Knost JA; Denning B
Cancer Treat Rep; 1982 Sep; 66(9):1729-32. PubMed ID: 6288237
[TBL] [Abstract][Full Text] [Related]
64. Progress report on vindesine treatment of melphalan-resistant multiple myeloma.
van Dobbenburgh OA; Houwen B; Halie MR; Marrink J; Ockhuizen T; Nieweg HO
Eur J Cancer Clin Oncol; 1983 Jun; 19(6):861-2. PubMed ID: 6683653
[No Abstract] [Full Text] [Related]
65. Phase I evaluation of vindesine in children: a Southwest Oncology Group pilot study.
Komp D; Vats T; Shepherd DA; Vietti T; Hoogstraten B; Haas CD
Med Pediatr Oncol; 1980; 8(3):243-50. PubMed ID: 7193278
[TBL] [Abstract][Full Text] [Related]
66. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
[TBL] [Abstract][Full Text] [Related]
67. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
[TBL] [Abstract][Full Text] [Related]
68. Vindesine in the treatment of advanced colorectal cancer: a phase II study.
Diaz-Rubio E; Martin-Jimenez M
Cancer Treat Rep; 1984 Mar; 68(3):555-6. PubMed ID: 6704985
[No Abstract] [Full Text] [Related]
69. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
70. Vindesine in the treatment of esophageal carcinoma: a phase II study.
Kelsen DP; Bains M; Cvitkovic E; Golbey R
Cancer Treat Rep; 1979; 63(11-12):2019-21. PubMed ID: 526935
[TBL] [Abstract][Full Text] [Related]
71. Vindesine. A phase II trial in advanced breast cancer patients.
Robins HI; Tormey DC; Skelley MJ; Falkson G; Crowley JJ; Ramirez G; Falkson H
Cancer Clin Trials; 1981; 4(4):371-5. PubMed ID: 7318120
[TBL] [Abstract][Full Text] [Related]
72. Evaluation of vindesine and MER in colorectal cancer.
Bedikian AY; Valdivieso M; Maroun J; Gutterman JU; Hersh EM; Bodey GP
Cancer; 1980 Aug; 46(3):463-7. PubMed ID: 6249481
[TBL] [Abstract][Full Text] [Related]
73. EORTC phase II trial of vindesine in advanced melanoma.
Rümke P; Everall JD; Mulder JH; Rozencweig M; Czarnetzki B; Thomas D
Eur J Cancer Clin Oncol; 1983 Aug; 19(8):1173-4. PubMed ID: 6684562
[No Abstract] [Full Text] [Related]
74. Vindesine: phase II evaluation in colon cancer and description of its platelet stimulating activity.
Pazdur R; Rossof AH; Chandra G; Bonomi PD; Slayton RE; Wolter J
Cancer Chemother Pharmacol; 1982; 9(1):41-4. PubMed ID: 7139851
[TBL] [Abstract][Full Text] [Related]
75. Continuous infusion vindesine in solid tumors.
Bodey GP; Yap HY; Yap BS; Valdivieso M
Cancer Treat Rev; 1980 Sep; 7 Suppl 1():39-45. PubMed ID: 7438120
[No Abstract] [Full Text] [Related]
76. Vindesine receptors in cells of a human leukaemia cell line.
Totsuka K; Oshimi K; Mizoguchi H
Br J Cancer; 1982 Sep; 46(3):392-6. PubMed ID: 6957239
[TBL] [Abstract][Full Text] [Related]
77. Plasma spermidine concentrations as early indication of response to therapy in human myeloma.
Van Dobbenburgh OA; Houwen B; Jurjens H; Marrink J; Halie MR; Nieweg HO
J Clin Pathol; 1983 Jul; 36(7):804-7. PubMed ID: 6863572
[TBL] [Abstract][Full Text] [Related]
78. Update results of vindesine as a single agent in the therapy of advanced malignant melanoma.
Retsas S; Peat I; Ashford R; Coe M; Maher J; Drury A; Hanham IW; Phillips RH; Newton KA; Westbury G
Cancer Treat Rev; 1980 Sep; 7 Suppl 1():87-90. PubMed ID: 7438128
[No Abstract] [Full Text] [Related]
79. A comparison of vindesine administration by bolus injection and by 24-hour infusion.
Gilby ED
Cancer Treat Rev; 1980 Sep; 7 Suppl 1():47-51. PubMed ID: 7438121
[No Abstract] [Full Text] [Related]
80. Vindesine trials at Memorial Sloan-Kettering Cancer Center.
Young CW
Cancer Treat Rev; 1980 Sep; 7 Suppl 1():53-7. PubMed ID: 7438122
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
